Campath-Arzerra trial for untreated CLLers

[Guest guest]

Northwestern University, Chicago has announced:

" This phase II trial studies the side effects and how well

giving alemtuzumab (Campath) and ofatumumab (Arzerra)

together works in treating patients with previously

untreated chronic lymphocytic leukemia (CLL). Monoclonal

antibodies, such as alemtuzumab and ofatumumab, can block

cancer growth in different ways. Some block the ability of

cancer to grow and spread. Others find cancer cells and help

kill them or carry cancer killing substances to them. Giving

alemtuzumab together with ofatumumab may kill more cancer cells "

Trial:NCT01361711

http://clinicaltrials.gov/ct2/show/NCT01361711

CLL CANADA

http://cllcanada.ca